The therapeutic community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s showing significant promise in clinical trials for treating obesity. Unlike some current weight loss approaches, retatrutide appears to provide a greater substantial decrease in body size and enhance metabolic function, particula